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Abstract: The purpose of this paper is to determine the factors in marketing most relevant to achieving 
pharmaceutical sales success and their interrelations, as well as providing a prescription-pharmaceuticals 
sales process model. This will enable scholars to obtain a better understanding of the marketing process 
for prescription pharmaceuticals, as well as enabling marketers to apply more efficient marketing 
approaches. The study uses a unique data set, combining primary data and secondary data from the 
Swiss prescription-pharmaceuticals market. The data is analysed using a multiple-regression based 
model. A multi-level data structure is found, suggesting that factors concerning the specific brand and 
also the pharmaceutical substance itself are relevant to sales success. It is revealed that the factors most 
relevant to sales success are: order of market entry, perceived product-quality, average price, and 
marketing expenditures, leading to practical recommendations for scholars and marketing professionals. 
The study focuses only on the Swiss prescription-pharmaceuticals market, investigating five medical drug 
classes. The assumption is made that these results can be generalised to similar markets and drug 
classes. The study develops a conceptual prescription-pharmaceuticals sales-process model; offers 
practical guidelines and a good basis for further scholarly research are provided; and identifies several 
research gaps by giving proposals for future research. 
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INTRODUCTION 
Pharmaceutical companies are increasingly 
facing pressure to compete. As a result, for many 
pharmaceutical companies, the revenues have 
been reduced resulting in smaller profit margins 
(Bush et al., 2002; Gonzalez et al., 2008). 
Because the efficacy of marketing spending is 
being questioned (Morgan et al., 2002; Sheth 
and Sisodia, 2002), pharmaceutical marketing 
managers are under increasing pressure 
to assess, justify and communicate the impact 
of marketing expenditures on financial 
outcomes” (Lehmann, 2004, p. 75), and 
therefore need to improve the efficacy of their 
marketing activities in order to reduce their 
marketing spend. 
 MARKETING IN THE PHARMA-
CEUTICAL SECTOR 
In pharmaceuticals marketing, marketers are 
generally considered to work within McCarthy´s 
(1960) conceptual framework. This refers to the 
four marketing instrument areas: product 
(includes product design, packaging), place 
(distribution channels), promotion (personal 
selling, advertising, sales promotion) and price 
(see Frey, 1956; Kotler, 1976). In the 
pharmaceutical business, it is clear that the sale 
(prescription decision) is to a greater or lesser 
extent influenced by the doctor’s personal 
medical-drug preference (prescription habit). 
Prior work has found that the prescription habit 
is guided by the order of market entry (OE) 
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(Coscelli, 2000). Therefore, an early market 
entry leads to that product gaining a market 
advantage, as found in a large number of prior 
studies (Berndt et al., 1997; Coscelli, 2000; 
Golder and Tellis, 1993; Kalyanaram and Urban, 
1992; Bond and Lean, 1977; Urban et al., 1986). 
Most of the current literature on pharmaceutical 
marketing presupposes the order of market entry 
model (OE) as a starting point in the conception 
of a marketing strategy (see also Castro and 
Chrisman, 1995; Rodriquez-Pinto et al., 2008). 
While it can be seen that there is some 
conflicting research, it can be said in general that 
the OE plays a crucial role in the development 
of the marketing strategy (see Castro and 
Chrisman, 1995; Rodríguez-Pinto et al., 2008). It 
can therefore be formally stated that ceteris 
paribus: 
H1: The earlier (in regard to other 
competitors) a market entrant enters the market, 
the higher the sales will be. 
Of course, in a prescription-pharmaceuticals 
market, the product features of a medical drug 
play a central role in the physician’s prescription 
decision (sales) (Cooper and Kleinschmidt, 
1993; Flechter, 1989; Kotler and Keller, 2006; 
Sharp and Dawes, 2001; Dogramatzis, 2002). 
For Cooper and Kleinschmidt (1993), product 
differentiation can be reached by the design 
or physical quality of competing products, by the 
efforts of sellers to distinguish their products 
through packaging and innovativeness, 
designed to win the allegiance and loyalty 
of potential buyers” (Bain 1956, p114; see also 
Chen and Burgers, 2007 and Kotler, 1998). 
In the product design area of pharmaceutical 
products, product innovativeness, efficacy and 
qualities such as safety (including tolerability) 
appear to be the key success factors (Smith, 
1983; Flechter, 1989; Dogramatzis, 2002). 
Product quality (efficacy, safety (including 
tolerability) has also been shown to play an 
important role in pricing. Consequently, if the 
approved product has an advantage relative 
to other products, its market share increases 
(Berndt et al., 1997). Within this context, several 
researchers (Smith, 1990; Flechter, 1989; 
Dogramatzis, 2002) describe the medical-drug 
interactions (IA), side effects (SE), efficacy and 
packaging as the most relevant product features. 
Taking these product-related factors together, 
a number of specific hypotheses can be 
generated: 
H2: Medical drugs with fewer IAs are 
more likely to be prescribed by practitioners. 
H3: Medical drugs with fewer SEs are 
more likely to be prescribed by practitioners. 
H4: The better the medical drug’s 
expected efficacy and effectiveness, the more 
likely it is that the medical drug will be 
prescribed. 
Furthermore, packaging is a part of product 
design that enables the manufacturers 
to distinguish themselves from the competition. 
Evidence suggests that doctors tend to prescribe 
the product with the most convenient package 
size, e.g. by choosing the most economical 
option for their patients. In addition to this it is 
suggested that producers with a wider range 
of different packaging have a benefit on market. 
This is supported by Wansink (1996) who 
concludes that the package's size influences 
usage volume. This is support of Elliot (1993) 
who states that increased competition is forcing 
brand managers of consumer goods to alter the 
portfolio of the package sizes they offer. It is 
therefore hypothesed: 
H5: Medical drugs supplied 
in a packaging more convenient for the user are 
more likely to be sold.  
The influence of pricing in the pharmaceutical 
sector has been investigated by several 
researchers. Lexchin (2009, p145) highlighted 
that doctors are generally ignorant both about 
the relative and absolute prices of medications”. 
Despite the contradicting evidence provided 
by the literature, it seems likely that in some 
manner, the price of a medical drug will be 
an important variable in any medical pricing 
policy. Even so, the influence of price on sales 
still remains quite unclear, and further research 
is thus required. As a baseline then, and in line 
with general market theory (see Arnold, 2008), 
a negative relation between the price level and 
the prescription decision is suggested: 
H6: Medical drugs with a lower price 
(price of medication) are more likely to be sold.  
In order to ensure that a product is known 
by physicians and, in turn, that prescriptions are 
made (see Brassington and Pettit, 2007), it is 
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important to market this product. Previous 
research has also shown that marketing 
expenditure (MA) has a significant and positive 
effect on sales in pharmaceutical markets. The 
relevance of promotion in pharmaceutical 
marketing has been described by Bond and 
Lean (1977), who found a linear function 
between sales (revenue) and promotion. These 
findings are supported by Kremer et al. (2008, 
p244), who showed that ‘promotional 
expenditure have a significant and positive effect 
on sales in pharmaceutical markets’. However, 
this has also been questioned by Kremer et al. 
(2008, p235), who concluded that the ‘main 
conclusion from studies on the product and 
disease category levels is that the effectiveness 
of promotional instruments remains unclear’. 
In addition, another aspect to be considered is 
the informational content of promotion and its 
role in prescription behaviour. Azoulay (2002, 
p551) revealed that product market competition 
in the pharmaceutical industry is shaped by both 
advertising rivalries and scientific rivalries”. 
However, Schwartz et al. (1989, p281) revealed 
that physicians also sometimes prescribed drugs 
at a rate far greater than that warranted 
by scientific evidence of their effectiveness”. 
As a result, the following hypothesis is proposed: 
H7: More (DTP) promoted medical 
drugs are more likely to be sold.  
The place of distribution (place) in the model is – 
like DTC advertising – usually dependent on the 
characteristics of the market itself. It should be 
noted that place (distribution), as a marketing 
instrument, does not appear to play an essential 
role in marketing success, according to some 
researchers (Cooper and Kleinschmidt, 1993; 
Ghosh et al., 1983; Smith, 1983). In many 
markets, pharmaceuticals are tightly controlled 
by governmental regulations, meaning that no 
variations are made regarding the distributional 
marketing activities by pharmaceutical 
companies. As such, considerations 
of distribution are removed from the model – 
while recognising that in a less restricted market, 
the distribution variable may play a different role. 
 RESEARCH METHODOLOGY AND 
DATA PREPARATION 
This study uses a unique set of primary and 
secondary data from the Swiss pharmaceutical 
sector. The applied secondary data were 
collected by a market-research company, 
via a network of associated doctors, 
pharmacists and wholesalers, by gathering data 
from the medical drugs sales transactions 
on a monthly basis. The data set covered a total 
of five prescription-drug classes, containing 
sales information on 37 substances from 108 
products (brands) in Switzerland for the period of 
1995 to 2005. As a result, approximately 2.5% 
of the total Swiss prescription market [total 
market volume: 4´052 million Swiss Francs 
(Kaech, 2005, p68)] are investigated. The Swiss 
market is an appropriate one, because its 
characteristics of governmentally-fixed pricing, 
the lack of price awareness of the prescribers 
and the patients when a drug choice is made, 
restrictions to certain promotional measures, 
and the almost non-existent competition from 
other markets, replicate many other large 
pharmaceutical markets (e.g. Dogramatzis, 
2002). In Table 1, a short description of the 
market segments and data is given. 
Tab. 1: Prescription Pharmaceutical Market Segments Data 
Market Segment Description 
Beta Blockers The dataset of Beta Blockers contains eight pharmaceutical substances and 25 medical 
products in total. 
ACE Inhibitors The market dataset of ACE inhibitors contains eight pharmaceutical substances and 30 
medical products (brands) in total. 
ATIIR 
Antagonists 
The data of Angiotensin II Antagonists contain six pharmaceutical substances and 10 
medical products (brands). 
PDE5 Inhibitors The market dataset of the therapeutic category phosphodiesterase type 5 inhibitors 
contains six pharmaceutical substances and 60 medical products in total. 
Statins The dataset of Statins (members of the lipid lowering class) contains five pharmaceutical 
substances and 20 medical products. 
Source: Own procesing, 2017
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The variables described in Table 2 covered each 
of the previously described markets segments 
shown in Table 1. However, because of the fact 
that the data did not contain specific product 
properties, data regarding the defined daily 
(drug) dose (DDD) were taken from the World 
Health Organization (WHO) database, while 
data about drug IAs and SE profiles were taken 
from a database provided by the Swiss 
prescription drugs approval authority 
(Swissmedic). In addition to this, because of the 
fact that no information regarding physicians’ 
expected efficacy and effectiveness was 
available, we gathered primary data from Swiss 
physicians using a questionnaire.  
In the first section of this questionnaire, a brief 
introduction to the research and survey was 
made. In the second section, the participants 
were asked to rank the medical substance 
on a semantic scale (1-9, not efficient to highly 
efficient, or no answer) as perceived by the 
participants and a comment section was 
included. These questions were then 
implemented using an online survey tool, 
in order to enable an email-directed survey 
approach. For this purpose, an online 
questionnaire was then distributed via a Swiss 
market research agency, reaching 6,000 
medical doctors (this is approximately 
a complete census of Swiss GPs). In total, 165 
completed questionnaires (response rate 2.5 %) 
were returned. It needs to be stated, at this point, 
that a low response rate to surveys among 
medical doctors is not unusual (Asch et al., 1997; 
Sloan et al., 1997).  
Tab. 2: Description and Statistics of Individual Scales 
Variable Description Hypotheses 
(OE) Order of 
Market Entry  
This variable indicates the order of market entry of a specific product within a 
specific medical drug class. 
H1 
(IA) Drug 
Interaction  
This variable indicates the „interaction between a drug and another substance 
that prevents the drug from performing as expected“ (Day, 2007, p53). 
H2 
(SE) Drug Side 
Effects  
This variable indicates the „adverse effect that can be termed as a side-effect 
when judged to be secondary to a therapeutic effect. Adverse effects may cause 
complications of a disease or procedure and negatively affect its prognosis (Day, 
2007, p196). 
H3 
(EEE) Expected 
efficacy and 
effectiveness  
This variable indicates the efficacy of a specific medical drug as perceived by 
prescribers in relation to other medical drugs within a specific drug class.  H4 
Packaging 
Alternatives (PA) 
This variable indicates the number of available package sizes. 
H5 
(AP) Average 
Price  
A price standardisation procedure was conducted to perform a price comparison 
between the different substances in terms of their efficacy, different dosages and 
packaging units within a medical drug class was conducted. The standardised 
price, for one day’s therapy is based on the defined daily drug dose (DDD), 
described as the „assumed average maintenance dose per day for a drug used 
for its main indication in adults’ (www.whocc.no). 
H6 
(DE) Detailing 
Expenditures  
This variable indicates the monthly personal selling (detailing) expenditures for a 
specific product (brand). 
- 
(ME) Mailing 
Expenditures  
This variable indicates the monthly direct mailing expenditures for a specific 
product (brand). 
- 
(AE) Advertising 
Expenditures  
This variable indicates the monthly advertising expenditures for a specific product 
(brand). 
- 
(MA) Marketing 
Expenditures  
Total monthly marketing expenditures, derived by the addition of detailing 
expenditures (DE), mailing expenditures (ME) and advertising expenditures (AE). 
H7 
(AS) Average 
Sales   
This variable indicates the stated real average sales of a specific medical drug 
per month. 
- 
(BS) Beta Sales  This variable indicates the slope (beta value) of sales. - 
Source: Own procesing, 2017
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Before building our model, we explored the data 
set for potential multicollinearity, given the 
likelihood of this occurring amongst key 
independent variables. In particular, a high 
correlation was observed between the marketing 
variables [detailing expenditures (DE), mailing 
expenditures (ME), advertising expenditures 
(AE)], indicating a high level of multicollinearity 
(Kleinbaum et al., 1998), which results 
in unstable statistical results (Cohen and Cohen, 
1975; Kleinbaum et al., 1998). Therefore, these 
variables were combined by calculating the 
monthly average, creating a composite 
marketing expenditures (MA) variable for further 
use.  
As a further descriptive investigation, a sales-
time diagram was produced in a next step. 
For this purpose, data from two medical drug 
class markets, ATIIR Antagonists and Statins, 
were analysed. Different slopes between the 
sales (revenue) curves were observed. Drawing 
from this, the variable beta sales (BS), as an 
indicator for the slope of sales (i.e. beta value), 
was introduced as a dependent variable 
to represent the growth (decline) of sales over 
time (see Table 2). While this seems relatively 
innovative in a marketing context, in economics, 
the idea of beta (slope) as a decisive factor is 
widely used (see Arnold, 2008).  
Furthermore, taking into consideration that some 
of the brands use the same substance (multiple 
brands can use the same substance, e.g. 
Paracetamol), a hierarchical two-level data 
structure is suggested, indicating a brand (first) 
and a substance (second) level. The substance 
level includes EEE, IA, and SE variables. The 
brand level, on the other hand, contains OE, 
packaging alternatives (PA), average price (AP)  
and MA as independent variables, whereas 
average sales (AS) results in a dependent 
variable (see Figure 1). 
 
Fig. 1: Multi-Level Market Data Structure 
 
 Source: Own, 2017
 REGRESSION ANALYSIS 
Because of the multi-level data structure, 
a hierarchical linear model (HLM) was 
considered (see Leeuw and Kreft, 1986; 
Longford, 1993; Kozlowski and Klein, 2000). 
However, in order to run a hierarchical linear 
model, methodological literature suggests 
a minimum sample size per level and group of 2 
and 30 respectively (Bell et al., 2008; Hox and 
Maas, 2002; Moineddin et al., 2007; Wieseke et 
al., 2008). Unfortunately, our data set does not 
reach this threshold, and because of the 
secondary nature of the market data set, the 
sample size cannot be expanded. We therefore 
used a multiple-regression analysis method 
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to conduct analysis for each level separately. 
The application of regression analysis is viewed 
as the best strategy for testing the given 
conceptual model. According to Hair et al. (1998, 
p. 20) a general statistical technique used 
to analyse the relationship between a single 
dependent variable and several independent 
variables”. The conducted regressions were 
based on the sample of 37 substances from 108 
brands. Since it is necessary for a separate 
multiple-regression analysis to be conducted for 
both levels, the data needed to be aggregated 
for the second level (Hox, 2010). For this 
purpose, first level (brand) data were taken and 
their average value for every single substance 
was calculated.  
For the analysis of the first-level model, the 
following independent variables were 
introduced: OE, AP, PA, MA, using AS 
as a dependent variable. For AP, support could 
be found (beta = 0.11; sig. = 0.08). For MA, 
strong support can be afforded by the results 
(beta = 0.42; sig. = 0.00). This means that 
an increase in AP and MA will lead to higher 
sales (revenue). Furthermore, it can be seen that 
hypotheses H1 and H5 do not find support. 
In other words, OE and PA do not influence the 
prescribing decision (see Table 3).  
For the second level (substance) multiple-
regression model, aggregated data were used. 
The analysis has shown that SE (beta = 0.42; 
sig. = 0.03) and EEE (beta = 0.37; sig. = 0.04) 
are significantly positively related to sales. 
On the other hand, no significant relationships 
were found for drug IA (see Table 3). 
Tab. 3: Results of the Multiple Regression Model of Average Sales 
Dependent Variable: Average Sales (AS) 
First Level (Brand) Regression Analysis 
Model Data:  R2 = 0.330;  F = 4.854;  Sig. = 0.000 
Independent Variable Beta Sig. Hypotheses 
Order of Market Entry (OE) -0.08 0.44 H1 
Packaging Alternatives (PA) 0.11 0.25 H5 
Average Price (AP) 0.11 0.08 H6 
Marketing Expenditures (MA) 0.42 0.00 H7 
Second Level (Substance) Regression Analysis 
Model Data:  R2 = 0.341;  F = 3.962;  Sig. = 0.021 
Independent Variable Beta Sig. Hypotheses 
Drug Interaction (IA) -0.06 0.76 H2 
Drug Side Effects (SE) 0.42 0.03 H3 
Expected Efficacy and Effectiveness (EEE) 0.37 0.04 H4 
Source: Own, 2017
The third model analysed the relationship 
between marketing factors and BS on the first 
level (brand). The analysis shows that OE (beta 
= 0.19; sig. = 0.07), EEE (beta = 0.46; sig. = 
0.00) and average MA (beta = 0.22; sig. = 0.03) 
are significantly positively related to sales (H1, 
H4, H6). On the other hand, no significant 
relationships were found for AP and PA (see 
Table 4).  
The fourth model analysed the relationship 
between marketing factors and the BS on the 
second level (substance), using aggregated 
data. The analysis indicates that IA (beta = -0.28; 
sig. = -2.06), SE (beta = 0.32; sig. = 2.34) and 
EEE (beta = 0.67; sig. = 0.00) are significant 
related to the sales slope (see Table 4).
  
Trendy v podnikání, roč. 7, číslo 2, s. 50-62, 2017.
Business Trends, vol.7, no. 2, p. 50-62, 2017.
Trendy v podnikání - Business Trends 2017/2 55
Tab. 4: Results of the Multiple Regression Model of Average Sales 
Dependent Variable: Beta Sales (BS) 
First Level (Brand) Regression Analysis 
Model Data:  R2 = 0.335;  F = 5.608;  Sig. = 0.000 
Independent Variable Beta Sig. Hypotheses 
Order of Market Entry (OE) 0.19 0.07 H1 
Packaging Alternatives (PA) 0.08 0.40 H5 
Average Price (AP) 0.05 0.65 H6 
Marketing Expenditures (MA) 0.22 0.03 H7 
Second Level (Substance) Regression Analysis 
Model Data:  R2 = 0.625;  F = 12.771;  Sig. = 0.000 
Independent Variable Beta Sig. Hypotheses 
Drug Interaction (IA) -0.28 0.05 H2 
Drug Side Effects (SE) 0.32 0.03 H3 
Expected Efficacy and Effectiveness (EEE) 0.67 0.00 H4 
Source: Own, 2017 
The outcome of the multiple-regression analysis, 
leading to the hypothesised antecedents to AS 
and their expected direction of influence is 
shown in Table 5. 
 
 Tab. 5: Hypothesised Independent Variables of Average Sales 
Hypotheses Independent Variable Expected Direction of 
Relationship (Sales) 
Support of 
Hypotheses 
H1 Order of Market Entry (OE)  - N 
H2 Drug Interaction (IA)  - N 
H3 Drug Side Effects (SE)  - N 
H4 Expected Efficacy and Effectiveness (EEE)  + Y 
H5 Packaging Alternatives (PA) + N 
H6 Average Price (AP)  - N 
H7 Marketing Expenditures (MA)  + Y 
Source: Own, 2017
 DISCUSSION 
The outcome of the analysis suggests a number 
of novel contributions to literature 
on pharmaceutical marketing. First, we uncover 
a multi-level structure, containing a brand (first) 
level and a substance (second) level. In practical 
terms, this distinction is highly relevant 
as companies are only able to actively influence 
non-substance level-related variables through 
their marketing activities. This means that 
marketers can only influence brand-related 
factors, whereas substance-related factors are 
mainly attributed when the outcomes 
of companies’ research and development are 
presented.  
Furthermore, our descriptive analysis suggested 
that during the early stage of market entry, sales 
appeared to increase immediately, but once 
a product is established on the market, no effect 
can be observed. Therefore, an additional 
variable [BS] was introduced, indicating the 
slope and capturing the overall sales trend, 
whereas the mean AS over the whole sales 
period is indicated by the AS variable. 
As a result, it can be concluded that promotional 
efforts in general are of importance during the 
medical drug introduction phase 
as an extraordinary sales increase takes place. 
The investigation of the OE has not revealed 
a significant relationship to AS, but a positive 
significant relation to BS. This means that a later 
market entrant is more likely to have a higher 
increase in sales during the market introduction 
than an earlier entrant. Even more interesting is 
the fact that AS is not related to OE. At first 
glance, it appears that OE is not necessarily 
a decisive factor for long-term market success 
(sales). This finding is also in contrast to the 
findings presented in the scientific literature (see 
Urban et al., 1986; Berndt et al., 1997; 
Kalyanaram and Urban, 1992; Bond and Lean, 
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1977; Golder and Tellis, 1993). However, in the 
present context, additional factors such 
as governmental bodies are involved in the 
medicines-launching process. Consequently, an 
early entry does not necessarily lead to higher 
sales.  
The analysis of the MA has revealed a high level 
of multicollinearity between the initial DE, ME 
and AE variables. This result suggests that little 
distinction in regard to the specific spending 
on marketing activities appears to be made by 
the pharmaceutical companies in the studied 
market.  
As an additional theoretical implication, this 
research has shown a negative significant 
correlation between the order of market entry 
(OE) as well as marketing expenditures (MA) 
(pears.corr = -0,349; sig = 0.001) as well 
average price (AP) (pears.corr = -0,451; sig = 
0.000). According to these data, for a later 
market entrant, less marketing expenditures are 
required but also a lower price is required. 
Therefore, marketing expenditures and average 
price are the mediators, whereas the order 
of market entry is the moderator. This is inline 
with the scientific literature (Bond and Lean, 
1977; Bowman and Gatignon, 1996; 
Kalyanaram, 2008). Furthermore, as positive 
significant correlation between the marketing 
expenditures and average price (pears.corr = 
0,549; sig = 0.000) was found. This means that 
higher marketing expenditures lower the price 
sensitivity allows therefore a price increase (see 
also Narayanan et al., 2004; Rizzo, 1999). In this 
case, marketing expenditures are the moderator 
whereas the average price is the mediator. 
Based on the results of the regression analysis, 
the following conceptual model can be 
presented (Figure 2):
Fig. 2: Two-Level Conceptual Model of Prescription-Pharmaceuticals Marketing in a State-Controlled 
Market 
 
Source: Own, 2017
For drug interaction (IA) the analysis did not 
reveal a significant relation to average sales (AS) 
but a negative relation to beta sales (BS). This 
means that more indicated drug interactions 
would result in a lower sales (revenue) increase 
(beta). While somewhat counter-intuitive at first 
glance, these findings are in support of the 
scientific literature. According to Berndt et al. 
(1997), sales (revenue) will increase if the 
approved product has an advantage relative 
to other products. However, this relationship 
may fluctuate in absolute magnitude across time 
was well as within and between various product 
classes. As such, the effect on BS indicates that 
over time, drugs with more indicated interactions 
have a generally decreasing sales trend. Yet, 
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their absolute sales may fluctuate to the extend 
that a relationship with average sales is not 
significant in our analysis.  
However, in support of previous research 
(Brassington and Pettit, 2007; Kremer et al., 
2008; Bond and Lean, 1977), a highly significant 
positive relation of MA to AS and BS found, 
emphasizing the importance of promotional 
activities for the sales success.  
The analysis of the product-related drug IA 
variable has revealed a negative relation to BS. 
This means that a higher number of drug IAs 
result in a lower increase of sales. These 
findings are in support of the scientific literature, 
as sales will increase if the approved product has 
an advantage relative to other products (Berndt 
et al., 1997).  
Of particular interest however is that a positive 
relationship between medical SE and both AS 
and BS was found. While this seems 
contradictory to logic, Denig et al. (1988, p. 82) 
revealed that for the acute disorder, efficacy is 
valued the most, followed by experience and 
only then are side effects taken into account”. 
Furthermore, Denig et al. (1988, p. 83) deduced 
that mild side effects seem to play a minor role 
in the assessment of medical drugs”. Of course, 
in the present context it needs to be stated that 
the data here do not distinguish between serious 
and mild SE. However, medical drugs that 
knowingly contain a seriously harmful SE profile 
are not normally introduced to the market. 
Consequently, in practical usage, it seems that 
practitioners do not take (mild) SE into account 
when prescribing a medical drug. Furthermore, 
a positive significant relationship between EEE 
and AS and BS was indicated. These findings 
are in line with Flechter’s (1989) conclusion that 
product confidence is relevant for the physician’s 
prescription decision (sales).  
For PA, no significant relationship with AS was 
found. These findings for the investigated market 
are not surprising, as many physicians also sell 
the prescribed medical drugs directly to their 
patients (see Kocher and Oggier, 2007). 
Therefore, economic packaging does not really 
play a role when a medical prescription is being 
made. 
In the light of the results, it appears that in regard 
to medical drug quality (product property), drug 
prescription decisions are made either 
on a prevailing misconception, such as lack 
of knowledge, or wrong or biased information, or 
prescription habit (see Denig et al., 1988). 
In other words, it is suggested by these results 
that practitioners are not always well informed 
and therefore do not prescribe the most suitable 
medical drug.  
Next, a significant relationship between AP and 
AS was found, revealing that higher medical 
drug prices result in higher sales. This is 
in contrast to the price elasticity of demand 
theory (see Arnold, 2008) that in a market with 
freely available substitutable products, a higher 
price will lead to lower sales. However, these 
results can be explained by the fact that 
prescribers seem not to be motivated 
to prescribe cheaper medical drugs. This is 
in support to other research conducted 
by Lexchin (2009) as well as Cooper and 
Kleinschmidt (1993) who concluded that a low-
price strategy is generally not effective. 
Furthermore, self-dispensing doctors, in order 
to maximise their profit (Kocher and Oggier, 
2007; Sutherland et al., 2008), are motivated 
to prescribe more expensive drugs. On the other 
hand, patients do not appear to be very cost-
sensitive either, as they do not have to cover the 
costs (see Newhouse and Marquis, 1978). This 
result is likely to be relatively unique to markets 
where patients do not contribute significantly 
to healthcare costs directly (e.g. markets where 
government subsidies from tax are high) – such 
as many European contexts. 
 PRACTICAL RECOMMENDATIONS 
FOR MARKETERS 
Based on the research findings, the following 
important practical recommendations are given, 
enabling pharmaceutical marketing-managers 
to improve the efficacy of the applied marketing 
activities and therefore to justify their marketing 
spending.  
 It is not essential to be first to market: 
A later market entrant can benefit from 
the early entrants’ market experience.  
 Implementing strong marketing 
activities during the launch phase is 
crucial: The study has revealed that 
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a higher increase in sales is usually 
gained during the product launch phase.  
 Enhance the prescriber’s expected 
efficacy and effectiveness: Marketers 
need to ensure that prescribers think 
highly of the quality of a specific medical 
drug, by conducting suitable marketing 
activities.  
 A high-price policy is beneficial in the 
right market: The circumstances 
in which those who receive a service 
and/or pay for it are not identical with 
those who make the decision (Harms et 
al., 2002) justify this effect. Furthermore, 
self-dispensing physicians increase 
their profits by selling the prescribed 
medication. Physicians are, therefore, 
not motivated to prescribe less 
expensive medical drugs.  
Apply the promotional activities more 
specifically: The promotional efficacy could be 
improved by implementing more target-oriented 
promotional activities. 
 LIMITATIONS AND DIRECTIONS FOR 
FUTURE RESEARCH 
Like any study, the present research has some 
limitations. This study was designed so that 
individual medications could be compared 
effectively with each other (same product class 
and same indication), leading to a limited 
number of medications available and a resulting 
small data set. Furthermore, the assumption is 
made that the presented results could be 
generalised for prescription-pharmaceuticals 
markets that are similar to the Swiss market. 
Of course, this might not necessarily be true 
(Kremer et al., 2008), especially because only 
five medical drug classes have been 
investigated. In addition, due to the fact 
of unavailable market data, we were unable 
to include a key aspect of sales success, namely 
patent protection, was not included in the study. 
Moreover, for the same reason, we were unable 
to collect data on some key controls (such as the 
equality of promotional budgets across brands.) 
for the investigated categories. Future work 
should, where possible, remedy these limitations 
(although in many cases it will be difficult 
to impossible to derive this data). It is important 
to study the effects of pharmaceutical marketing 
within a regulated prescription-drug market; 
however, it is often the case that the answers 
to research questions regarding marketing 
factors lead to new research questions. 
Consequently, this work delivers implications 
from which academics and marketers can 
benefit. However, this work has also revealed 
research gaps that interested scholars can 
follow in their research. Nevertheless, it should 
be highlighted at this point that the ‘primary goal 
of scholarship in pharmaceutical marketing 
should perhaps not be to derive theories that can 
be generalised perfectly to all situations’, 
as suggested by Stremersch (2008, p233). 
Rather, the goal should be to develop theories 
and reveal findings with explicit reference to the 
context (Steenkamp, 2005). In addition, 
academics should also gain unique overall and 
independent knowledge about a state-regulated 
pharmaceutical market and its specific 
behaviour, in order to be able to deliver 
recommendations to marketers and 
policymakers (Steenkamp, 2005). As a result, 
the following six research gaps are indicated. 
 Factors influencing expected efficacy 
and effectiveness: The prescriber’s 
perceptions of quality are of high 
relevance. However, the actual factors 
influencing the EEE still remain unclear. 
Therefore, additional research 
regarding the role and the guiding 
criteria behind EEE should be 
conducted. 
 Price elasticity of prescription-
pharmaceutical marketing-demand 
models: More research regarding the 
price elasticity that would cover more 
markets as well as the relevant guiding 
factors could be performed. This would 
be in support of Kremer et al. (2008, 
p. 236), who concluded that, in the 
literature, there is little consensus on the 
price elasticity of demand”. 
 Generalisation of the research results: 
This research is based on data taken 
from five prescription-pharmaceutical 
medication classes. However, 
according to Kremer et al. (2008, 
p. 244), the effects of the promotional 
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instruments vary considerably across 
disease categories”. Therefore, 
additional research could investigate 
whether the presented findings relate 
only to these five investigated medical 
classes, or if they can be generalised 
to the entire market.  
 The role of distribution and order-of-
market entry: There is room for further 
research regarding distribution and the 
relationship between order-of-market 
entry and distribution in prescription 
pharmaceutical marketing, as this is 
widely uncovered by the scientific 
literature (e.g. to be in hospital first). 
 The aspect of sales- patent protection 
can be investigated. 
 Marketing-mix concept: In addition 
to these five suggested research 
directions, it might be worth 
reconsidering the validity of the 4Ps 
Marketing Mix concept for prescription-
pharmaceuticals marketing. 
Alternatively, concepts such as 3Ps 
(product, price and promotion) might be 
suggested.  
 Despite of the fact that in the 
investigated market direct DTC 
measures cannot be conducted, the 
relevance of indirect DTC measures 
in pharmaceutical marketing could be 
investigated in a future study. 
This paper aims to shed light on the sales 
process in the pharmaceutical industry and 
to provide some managerial guidelines. The 
authors hope that this study provides a point 
of departure for further scholarly work in this 
fascinating and important area. 
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